Previous 10 | Next 10 |
Exelixis, Inc. (EXEL) BofA Global Healthcare Conference September 16, 2020, 12:35 pm ET Executives Mike Morrissey - President, Chief Executive Officer Analysts Jason Gerberry - Bank of America Merrill Lynch Presentation Jason Gerberry All right. Good afternoon, good e...
Exelixis, Inc. (EXEL) Morgan Stanley Global Healthcare Conference September 16, 2020, 15:30 ET Company Participants Michael Morrissey - CEO, President & Director Conference Call Participants Jeff Hung - Morgan Stanley Presentation Jeff Hung Welcome to the Morgan S...
Exelixis (NASDAQ: EXEL ) and Iconic Therapeutics announce new preclinical data that support the continued development of ICON-2, an ADC comprised of an anti-Tissue Factor (TF) antibody and Zymeworks’ proprietary linker-payload, for the treatment of diverse solid tumors. More new...
- ICON-2 is pharmacologically more potent in vivo and in vitro , with better nonclinical tolerability, compared with a monomethyl auristatin E (MMAE) anti-TF antibody-drug conjugate (ADC) - - Data presented this week at the World ADC Digital Conference - Exelixis, Inc. (Nas...
- Online event will be accessible at www.exelixis.com - Exelixis, Inc. (Nasdaq: EXEL) today announced it will host an investor briefing to discuss data presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020. The online-only event will be held following ...
When the S&P 500 lost 4.3% in two days last week, some of our bull market enthusiasm may have faded. And many of us were probably thinking back to the March market crash . Are we prepared for the next one? It may not be right around the corner, but it's never too early to prepare for oppo...
- Presentations to be webcast on www.exelixis.com - Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following virtual investor conferences in September: Morgan Stanley 18 th Annual Glo...
Pardon the pun, but investors have received a crash course on the unpredictability of short-term stock market movements in 2020. During the first quarter, panic and uncertainty stemming from the coronavirus pandemic chopped down the broad-based S&P 500 by 34% in just 33 calendar days. Thi...
Exelixis ( EXEL -2.3% ) has collaborated with privately-held NBE Therapeutics to discover and develop multiple antibody-drug conjugates ((ADCs)) for oncology indications, based on NBE’s ADC platform. More news on: Exelixis, Inc., Healthcare stocks news, Read more ...
- Companies will partner to develop novel antibody-drug conjugates using NBE’s unique ADC platform - - Agreement encompasses an exclusive option on multiple targets over a two-year term, with potential to extend time and scope of the collaboration - - Deal is the fourt...
News, Short Squeeze, Breakout and More Instantly...
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2024 financial results will be released on Tuesday, August 6, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Ex...
2024-07-11 08:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...